open access

Vol 5 (2020): Continuous Publishing
CASE REPORTS
Published online: 2020-02-06
Get Citation

Acute central serous chorioretinopathy — an uncommon complication of imatinib mesylate (imatinib) therapy in chronic myelogenous leukaemia

Sanjay Kumar Mishra, Ashok Kumar
DOI: 10.5603/OJ.2020.0003
·
Ophthalmol J 2020;5:8-11.

open access

Vol 5 (2020): Continuous Publishing
CASE REPORTS
Published online: 2020-02-06

Abstract

Imatinib is the most widely used drug in targeted therapy for chronic myelogenous leukaemia (CML). Few ophthalmic side effects like periorbital oedema, epiphora, ptosis, extraocular muscle palsy, blepharoconjunctivitis, glaucoma, papilledema, photosensitivity, retinal haemorrhage, and increased intraocular pressure are described with imatinib therapy. A 35-year-old male, a known case of CML with no ocular complaints, on treatment with imatinib for the preceding six weeks, presented with acute central serous chorioretinopathy in the left eye. Owing to his professional requirements for early visual recovery, he was treated with subthreshold micropulse laser with complete resolution of the subretinal fluid. This case report highlights acute central serous chorioretinopathy as a potential rare complication of imatinib therapy in CML patients, which requires regular and detailed ophthalmic evaluation so as to diagnose and treat it without any residual effects.

Abstract

Imatinib is the most widely used drug in targeted therapy for chronic myelogenous leukaemia (CML). Few ophthalmic side effects like periorbital oedema, epiphora, ptosis, extraocular muscle palsy, blepharoconjunctivitis, glaucoma, papilledema, photosensitivity, retinal haemorrhage, and increased intraocular pressure are described with imatinib therapy. A 35-year-old male, a known case of CML with no ocular complaints, on treatment with imatinib for the preceding six weeks, presented with acute central serous chorioretinopathy in the left eye. Owing to his professional requirements for early visual recovery, he was treated with subthreshold micropulse laser with complete resolution of the subretinal fluid. This case report highlights acute central serous chorioretinopathy as a potential rare complication of imatinib therapy in CML patients, which requires regular and detailed ophthalmic evaluation so as to diagnose and treat it without any residual effects.

Get Citation

Keywords

imatinib mesylate (imatinib); chronic myelogenous leukaemia (CML); central serous chorioretinopathy

About this article
Title

Acute central serous chorioretinopathy — an uncommon complication of imatinib mesylate (imatinib) therapy in chronic myelogenous leukaemia

Journal

Ophthalmology Journal

Issue

Vol 5 (2020): Continuous Publishing

Pages

8-11

Published online

2020-02-06

DOI

10.5603/OJ.2020.0003

Bibliographic record

Ophthalmol J 2020;5:8-11.

Keywords

imatinib mesylate (imatinib)
chronic myelogenous leukaemia (CML)
central serous chorioretinopathy

Authors

Sanjay Kumar Mishra
Ashok Kumar

References (9)
  1. Singhal MK, Sengar M, Nair R. Summary of the published Indian data on chronic myeloid leukemia. South Asian J Cancer. 2016; 5(3): 162–165.
  2. O'Brien SG, Guilhot F, Larson RA, et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348(11): 994–1004.
  3. Rennie I. Ophthalmic manifestations of childhood leukaemia. Br J Ophthalmol. 1992; 76(11): 641.
  4. Sharma T, Grewal J, Gupta S, et al. Ophthalmic manifestations of acute leukaemias: the ophthalmologist's role. Eye (Lond). 2004; 18(7): 663–672.
  5. Fraunfelder FW, Solomon J, Druker BJ, et al. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003; 19(4): 371–375.
  6. Montero J, Cervera E, Palomares P, et al. Serous retinal detachment as a presenting feature of chronic myelogenous leukemia. Retin Cases Brief Rep. 2010; 4(4): 394–396.
  7. Nakashima S, Kakugawa T, Motomura H, et al. Development of imatinibmesylate-induced interstitial lung disease 2 weeks after discontinuation of the treatment: a case report. Multidiscip Respir Med. 2012; 7(1): 48.
  8. Thanopoulou E, Judson I. The safety profile of imatinib in CML and GIST: long-term considerations. Arch Toxicol. 2012; 86(1): 1–12.
  9. Pietras K, Ostman A, Sjöquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001; 61(7): 2929–2934.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

VM Media sp. z o.o. VM Group sp.k., Grupa Via Medica, 73 Świętokrzyska St., 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl